Literature DB >> 33400996

Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.

Kevin F Boehnke1, Joel J Gagnier2, Lynne Matallana3, David A Williams4.   

Abstract

Cannabidiol (CBD) is widely advertised as helpful for chronic pain management but research is limited. Using a cross-sectional, anonymous survey, we examined patterns of naturalistic CBD use among individuals with fibromyalgia (FM) and other chronic pain conditions. Our objective was to better understand rates of CBD use, reasons for use and discontinuation, communication with healthcare professionals about CBD, and perceptions of CBD effectiveness and safety among people with FM. After excluding incomplete surveys, our study population consisted of N = 2,701 participants with fibromyalgia, primarily in the United States. Overall, 38.1% reported never using CBD, 29.4% reported past CBD use, and 32.4% reported current CBD use. Past-year cannabis use was strongly associated with past or current CBD use. Those using CBD typically did so due to inadequate symptom relief, while those not using CBD typically cited safety concerns as their reason for not using CBD. Two-thirds of participants disclosed CBD use to their physician, although only 33% asked for physician advice on using CBD. Participants used CBD for numerous FM-related symptoms (most commonly pain), and generally reported slight to much improvement across symptom domains. Around half of participants reported side effects, which were typically minor. Our findings are limited by selection bias and our cross-sectional design, which prevents causal associations. In conclusion, CBD use is common among individuals with FM and many individuals using CBD report improvements across numerous FM-related symptoms. Our findings highlight the need for additional rigorous studies to better understand CBD's potential for FM management. PERSPECTIVE: This article indicates that CBD use is common among people with fibromyalgia, and the results suggest that many derive benefit from using CBD across multiple symptoms domains. Clinicians should discuss CBD use with fibromyalgia patients, and future studies are needed to rigorously assess CBD's therapeutic value for fibromyalgia symptoms.
Copyright © 2021 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fibromyalgia; cannabidiol; chronic pain; prevalence; symptom relief

Year:  2021        PMID: 33400996     DOI: 10.1016/j.jpain.2020.12.001

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  8 in total

Review 1.  Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain.

Authors:  Mary-Ann Fitzcharles; Frank Petzke; Thomas R Tölle; Winfried Häuser
Journal:  Drugs       Date:  2021-11-20       Impact factor: 9.546

Review 2.  Approach to Diagnosis and Management of Chronic Pelvic Pain in Women: Incorporating Chronic Overlapping Pain Conditions in Assessment and Management.

Authors:  Sara R Till; Reina Nakamura; Andrew Schrepf; Sawsan As-Sanie
Journal:  Obstet Gynecol Clin North Am       Date:  2022-06       Impact factor: 2.838

Review 3.  Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain).

Authors:  Kevin F Boehnke; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Curr Rheumatol Rep       Date:  2022-05-03       Impact factor: 4.686

4.  Substituting Cannabidiol for Opioids and Pain Medications Among Individuals With Fibromyalgia: A Large Online Survey.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-05-13       Impact factor: 5.820

5.  Cannabidiol (CBD) Use among children with juvenile idiopathic arthritis.

Authors:  Christopher J Failing; Kevin F Boehnke; Meredith Riebschleger
Journal:  Pediatr Rheumatol Online J       Date:  2021-12-13       Impact factor: 3.054

6.  A mixed methods analysis of cannabis use routines for chronic pain management.

Authors:  Kevin F Boehnke; Laura Yakas; J Ryan Scott; Melissa DeJonckheere; Evangelos Litinas; Suzanne Sisley; Daniel J Clauw; David A Williams; Jenna McAfee
Journal:  J Cannabis Res       Date:  2022-01-11

Review 7.  Efficacy, Safety, and Regulation of Cannabidiol on Chronic Pain: A Systematic Review.

Authors:  Maria Resah B Villanueva; Narges Joshaghani; Nicole Villa; Omar Badla; Raman Goit; Samia E Saddik; Sarah N Dawood; Ahmad M Rabih; Ahmad Niaj; Aishwarya Raman; Manish Uprety; Maria Calero; Safeera Khan
Journal:  Cureus       Date:  2022-07-16

8.  Cannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia.

Authors:  Kevin F Boehnke; Joel J Gagnier; Lynne Matallana; David A Williams
Journal:  J Pain       Date:  2021-06-30       Impact factor: 5.820

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.